Kite Pharma

Kite Pharma, a subsidiary of Gilead Sciences, is a global leader in cell therapy focused on treating and potentially curing cancer. Their technology harnesses the power of a patient's own immune system by modifying their white blood cells to target and attack cancer cells. This individualized, one-time treatment approach offers hope for a cure for many patients with certain types of blood cancer. Kite is dedicated to advancing the understanding of cell therapy as a transformational treatment option and has a robust pipeline of therapies in development, including novel ways to improve patients' responses, different cell therapy modalities, and efforts to increase the speed of manufacturing.

Kite is committed to ensuring access to these therapies for as many eligible patients as possible. They have a global manufacturing network that delivers cell therapies rapidly and reliably, and they are actively working to expand their reach and make this innovative treatment accessible to a wider range of patients. They are also focused on promoting diversity and inclusion in clinical trials to ensure that historically underrepresented groups have access to the latest advancements in medicine.

Kite Pharma does not explicitly mention job flexibility or remote work options on their website or in the job postings provided.

Kite Pharma's mission is to transform cancer treatment through cell therapy, with a singular focus on developing and delivering innovative therapies that treat and potentially cure cancer. Their goal is to bring the promise of cell therapy to as many eligible patients as possible, leveraging the power of a patient's own immune system to target and attack cancer cells.

Kite Pharma promotes a culture that is centered around patient care and innovation. They emphasize the importance of their team working together to develop and deliver potentially life-saving cell therapies to cancer patients. They are committed to creating an inclusive work environment that values diversity and equity. Kite values collaboration, urgency, and the pursuit of excellence in all of their endeavors.

Kite Pharma, a Gilead Company, recognizes that diversity, equity, and inclusion are crucial for achieving equitable healthcare access and advancing medical research. They are committed to addressing disparities in clinical research, specifically in CAR T-cell therapy, by actively promoting diversity, equity, and inclusion in clinical trials. This includes fostering trust among diverse communities, identifying clinical trial sites that serve diverse populations, and including diverse research teams to build a more inclusive environment for scientific innovation.